A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy
Principal Investigator
Baljinder SalhOverview
Body Locations and Systems
Crohn's DiseaseClinicalTrials.gov#
NCT02365649Status
Closed for RecruitmentStudy Start/End
Jul 23, 2015 to Dec 1, 2016Locations
Diamond Health Care Centre, Vancouver General Hospital
Name/Title
Keri Earnshaw, Research Nurse Phone
604-875-5224Purpose of Study
To determine the efficacy and safety of multiple doses of ABT-494 in subjects with moderately to severely active Crohn's Disease with a history of inadequate response to or intolerance to anti-Tumor Necrosis Factor (TNF) therapy.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.